Chronic Lymphocytic Leukemia Clinical Trial

Lipoprotein Lipase Expression in Chronic Lymphocytic Leukemia

Summary

The investigators hypothesize that Lipoprotein Lipase (LPL) expression on Chronic Lymphocytic Leukemia (leukemia-cll/" >CLL) cells will predict a more aggressive clinical course. The results from this proposal will validate the use of a novel antibody developed at Dartmouth-Hitchcock in CLL and will predict CLL patients that have a more aggressive form of the disease. The investigators work will also provide direct evidence that LPL is expressed on CLL cells and provides a critical source of fatty acids required by the CLL cells to grow and survive. Fatty acid metabolism may become a therapeutic target in CLL in the future.

View Full Description

Full Description

The investigators plan to use a novel antibody developed at Dartmouth-Hitchcock Medical Center to characterize the expression of LPL in CLL. Peripheral blood from CLL patients will be analyzed by flow cytometry to detect the expression of LPL and to investigate if LPL expression correlates with a more aggressive type of CLL. The investigators propose that LPL protein expression on CLL cells is prognostic and that LPL and other proteins involved in fatty acid metabolism are critical for CLL cells to survive.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Diagnosis of CLL as per National Cancer Institute Working Group Guidelines
Patients undergoing routine blood draws as part of their ongoing follow up for CLL
18 years or older
Ability to provide consent in English
Patient must have measurable disease as defined by an absolute lymphocyte count greater than 5,000/mm3 or have archived lymph node or bone marrow with CLL involvement.

Exclusion Criteria:

Patients who have received cytotoxic drug, oral or intravenous steroid or targeted antibody therapy for their CLL,
other hematologic malignancy or other disease process within the past 6 months are excluded.

Study is for people with:

Chronic Lymphocytic Leukemia

Estimated Enrollment:

29

Study ID:

NCT01460238

Recruitment Status:

Completed

Sponsor:

Dartmouth-Hitchcock Medical Center

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Dartmouth-Hitchcock Medical Center
Lebanon New Hampshire, 03756, United States

How clear is this clinincal trial information?

Study is for people with:

Chronic Lymphocytic Leukemia

Estimated Enrollment:

29

Study ID:

NCT01460238

Recruitment Status:

Completed

Sponsor:


Dartmouth-Hitchcock Medical Center

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider